MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $363.03 million. The enterprise value is $232.17 million.
Important Dates
The last earnings date was Tuesday, March 11, 2025, after market close.
| Earnings Date | Mar 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 105.85 million shares outstanding. The number of shares has increased by 1.53% in one year.
| Current Share Class | 105.85M |
| Shares Outstanding | 105.85M |
| Shares Change (YoY) | +1.53% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 95.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.40 |
| Forward PS | 8.90 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.88, with a Debt / Equity ratio of 0.09.
| Current Ratio | 10.88 |
| Quick Ratio | 10.09 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.73% and return on invested capital (ROIC) is -13.47%.
| Return on Equity (ROE) | -18.73% |
| Return on Assets (ROA) | -12.60% |
| Return on Invested Capital (ROIC) | -13.47% |
| Return on Capital Employed (ROCE) | -22.89% |
| Revenue Per Employee | $270,119 |
| Profits Per Employee | -$287,098 |
| Employee Count | 143 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.67 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.93% in the last 52 weeks. The beta is 1.20, so MaxCyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.20 |
| 52-Week Price Change | -11.93% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 4.12 |
| Relative Strength Index (RSI) | 34.56 |
| Average Volume (20 Days) | 573,964 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MaxCyte had revenue of $38.63 million and -$41.06 million in losses. Loss per share was -$0.39.
| Revenue | 38.63M |
| Gross Profit | 31.53M |
| Operating Income | -51.20M |
| Pretax Income | -35.43M |
| Net Income | -41.06M |
| EBITDA | -46.88M |
| EBIT | -51.20M |
| Loss Per Share | -$0.39 |
Full Income StatementBalance Sheet
The company has $154.48 million in cash and $18.03 million in debt, giving a net cash position of $136.45 million or $1.29 per share.
| Cash & Cash Equivalents | 154.48M |
| Total Debt | 18.03M |
| Net Cash | 136.45M |
| Net Cash Per Share | $1.29 |
| Equity (Book Value) | 206.25M |
| Book Value Per Share | 1.95 |
| Working Capital | 155.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.61 million and capital expenditures -$1.65 million, giving a free cash flow of -$29.26 million.
| Operating Cash Flow | -27.61M |
| Capital Expenditures | -1.65M |
| Free Cash Flow | -29.26M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
Gross margin is 81.62%, with operating and profit margins of -132.54% and -106.29%.
| Gross Margin | 81.62% |
| Operating Margin | -132.54% |
| Pretax Margin | -106.29% |
| Profit Margin | -106.29% |
| EBITDA Margin | -121.37% |
| EBIT Margin | -132.54% |
| FCF Margin | n/a |